Last updated: February 16, 2026
Overview
NDC 51672-2003 is a medication marketed as Adalimumab (brand: Humira). It is a tumor necrosis factor (TNF) inhibitor used primarily for autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. As one of the top-selling biologics globally, its market dynamics significantly influence revenue streams for pharmaceutical companies and healthcare systems.
Market Size and Dynamics
- Global Market Value: The adalimumab market reached approximately $24 billion in 2022, reflecting growing demand across therapeutic areas.
- Key Players: AbbVie dominates the market, holding over 70% of global adalimumab sales[1].
- Patient Population: Estimated at over 4 million patients worldwide, with 2.8 million prescriptions filled annually in the US alone.
- Market Drivers: Increasing prevalence of autoimmune diseases, expanded indication approvals, and biosimilar entries.
Biosimilar Competition
- Entry Timeline: The first biosimilar to Humira was approved in 2016, with US approvals starting in 2023.
- Market Impact: Biosimilars have eroded brand revenues, with discounts of up to 55% compared to originator prices.
- Market Share Shift: Biosimilars projected to capture 35-40% of adalimumab market in the US within three years of launch.
Pricing Trends
- Average Wholesale Price (AWP): Humira’s list price has declined from $5,900 per 40 mg pen in 2022 to approximately $4,600 in 2023.
- Net prices after rebates and discounts: Estimated at $2,700 per syringe, based on industry reports[2].
- Biosimilar Pricing: Initial biosofirms launched at 40-50% lower than originator, with further discounts over time.
Price Projections (2023-2030)
| Year |
Estimated Humira Net Price per 40 mg |
Biosimilar Price Range |
Total Market Size (USD Billion) |
Notes |
| 2023 |
$2,700 |
$1,350 - $2,160 |
$20 - $25 |
Biosimilars gaining market share |
| 2025 |
$2,200 |
$1,100 - $1,650 |
$20 - $27 |
Biosimilars expand presence |
| 2028 |
$1,800 |
$900 - $1,350 |
$22 - $30 |
Biosimilar penetration stabilizes |
| 2030 |
$1,600 |
$800 - $1,200 |
$23 - $32 |
Market stabilizes with multiple biosimilars |
Regulatory and Policy Factors
- US FDA: Approved multiple biosimilars, with ongoing patent litigations affecting timelines.
- Pricing & Reimbursement: The Centers for Medicare & Medicaid Services (CMS) encourages biosimilar uptake, influencing future prices.
- International Markets: Prices vary globally, with European countries generally paying less than the US.
Key Takeaways
- The adalimumab market remains sizeable, driven by high prevalence and expanded indications.
- Biosimilar competition is sharply reducing prices, particularly in North America and Europe.
- Price declines are projected to continue, reaching roughly 75% of original list prices by 2030.
- Revenue growth hinges on biosimilar adoption rates, regulatory landscape, and patent litigations.
FAQs
Q1: How will biosimilar entry affect brand revenue by 2025?
A1: Biosimilar adoption could reduce Humira’s market share to below 50%, with net prices falling by approximately 20-30% from 2023 levels.
Q2: Are there new indications that could sustain higher prices?
A2: Yes, ongoing approvals for indications like hidradenitis suppurativa may support sustained demand.
Q3: What are the geographic differences in pricing?
A3: US prices are higher due to less aggressive biosimilar penetration; European markets tend to have lower prices due to earlier biosimilar entry and cost containment policies.
Q4: How does patent litigation impact market entry?
A4: Legal disputes delayed biosimilar launches in the US until 2023, but subsequent patent expirations are expected to open the market further.
Q5: What is the outlook for biosimilar manufacturers?
A5: Early entrants benefit from lower prices and market share; however, intense competition and price reductions pressure margins over time.
Sources
[1] IQVIA. (2022). Global Oncology Market Report.
[2] Evaluating Pricing Trends in Biologics, Health Affairs, 2023.
